Cardiology Associations

This page includes news coverage of cardiology societies and associations. Follow these links for specific cardiology society news pages: American College of Cardiology (ACC), American Heart Association (AHA), American Society of Echocardiography (ASE), American Society Nuclear Cardiology (ASNC), European Society of Cardiology (ESC), Heart Rhythm Society (HRS), Society for Cardiovascular Angiography Interventions (SCAI), Society of Cardiovascular Computed Tomography (SCCT), Transcatheter Cardiovascular Therapeutics (TCT), and Vascular Interventional Advances (VIVA).

AI-based coronary plaque evaluations highlight elevated heart risks in women
“This is the perfect technique to identify high-risk patients who would benefit from intensive therapies,” imaging specialist Gudrun Feuchtner, MD, told Cardiovascular Business.
Death after 1 year more common for real-world low-risk TAVR patients than those treated in clinical trials
Real-world patients were still associated with "excellent" outcomes, but it is important for cardiologists and patients alike to know as much as possible about the odds of survival following treatment.
No longer the ‘forgotten valve’: Tricuspid valve surgery outcomes keep improving
Patient outcomes after tricuspid valve replacement have improved significantly over the years, according to new data published in The Annals of Thoracic Surgery.
Implantable IVC sensor shows early potential to guide heart failure management
The goal is to measure changes in a patient’s IVC area and collapsibility, which can help anticipate when heart failure events might occur. This first-in-human study included data from the first 50 patients to receive the device.
New drug reverses antiplatelet effects of ticagrelor, helping surgeons avoid a 'bloody mess'
Deepak Bhatt, MD, believes bentracimab could be a game-changer if it gains approval. "I think it's the sort of drug that every emergency room and ICU would have to stock," he said. "A cardiac care unit would have to stock a couple of doses, as would every cath lab."

Heart attack deaths down in US: ‘We’re making progress in the right direction’

The study, to be presented March 5 at ACC.23/WCC in New Orleans, examined outcomes data from 1999 to 2020.

Daily marijuana use significantly increases risk of coronary artery disease

Monthly marijuana use, meanwhile, was not associated with a greater CAD risk. The full study is scheduled to be presented at ACC.23/WCC in New Orleans.

Sahil A. Parikh, MD, Director of Endovascular Services at Columbia University Irving Medical Center and Associate Professor of Medicine at the Columbia University College of Physicians and Surgeons, explained the growing trend or interventional cardiologists treating PAD and CLI. He shares what he thinks is important for cardiology departments to know before expanding expanding their programs in this space.

What do interventional cardiologists need to treat PAD and CLI?

Sahil Parikh, MD, director of endovascular services at Columbia University Irving Medical Center, said treating these patients can be quite challenging.

Hormone therapy for gender dysphoria linked to higher cardiovascular risks

“It's all about risks and benefits," one researcher said. "Starting transitioning is a big part of a person's life and helping them feel more themselves, but hormone replacement therapy also has a lot of side effects—it's not a risk-free endeavor."

Confirmed: Long COVID more than doubles a person’s risk of heart issues

According to a new analysis of data from nearly six million patients, experiencing long-lasting COVID-19 symptoms more than doubles the risk of cardiac complications.

Tim Attebery, DSc, MBA, the CEO of Cardiovascular Associates of America and former CEO of the American College of Cardiology (ACC)

Q&A: Tim Attebery on why private equity-backed management companies are investing in cardiology

The CEO of Cardiovascular Associates of America, and former CEO of the American College of Cardiology, shared his perspective on the rise of private equity investments in cardiology.

New ACC/AHA/SCAI guidance highlights training requirements for interventional cardiologists

The document, which was designed to help guide both interventional cardiology trainees and program directors, was also endorsed by several other industry societies.

Bertram Pitt, MD, a professor of medicine emeritus at the University of Michigan School of Medicine, explains the role of sodium–glucose co-transporter-2 (SGLT-2) inhibitors for heart failure (HF). Initially developed to treat diabetes, these drugs have been shown to improve HF outcomes in HF in several large, randomized trials over the past few years, including SOLOIST-WHF, DAPA-HF, EMPEROR-Preserved, and the DELIVER trials. The positive results earned their inclusion in the 2022 AHA/ACC/HFSA Guideline for

What clinical research tells us about sotagliflozin and heart failure

Some SGLT2 inhibitors have been linked to significant improvements in HF outcomes, but what about sotagliflozin? We spoke with Bertram Pitt, MD, to learn more.

Cardiology Associations

AI-based coronary plaque evaluations highlight elevated heart risks in women

Death after 1 year more common for real-world low-risk TAVR patients than those treated in clinical trials

No longer the ‘forgotten valve’: Tricuspid valve surgery outcomes keep improving

Implantable IVC sensor shows early potential to guide heart failure management

New drug reverses antiplatelet effects of ticagrelor, helping surgeons avoid a 'bloody mess'